Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Congratulations to Professor Andrew Pollard, named as one of three 2019 Rosén von Rosenstein laureates.

The Rosén von Rosenstein Medal is awarded by the University of Uppsala, Sweden

Andy Pollard receives the Rosen von Rosenstein MedalThe Rosén von Rosenstein Medal, awarded by the Swedish Paediatric Society and the Swedish Society of Medicine every five years since 1964, is recognised as the most prestigious prize within paediatrics.

Andrew Pollard is Professor of Paediatric Infection and Immunity at the University of Oxford, Director of the Oxford Vaccine Group, Honorary Consultant Paediatrician at Oxford Children’s Hospital and Vice Master of St Cross College. His research includes the design, development and clinical evaluation of vaccines including those for meningococcal disease and enteric fever and leads studies using a human challenge model of (para)typhoid. He runs surveillance for invasive bacterial diseases and studies the impact of pneumococcal vaccines in children in Nepal; he also leads a project on burden and transmission of typhoid in Nepal, Bangladesh and Malawi, and co-leads typhoid vaccine impact studies at these sites. He has supervised 37 PhD students and his publications includes over 500 manuscripts and books on various topics in paediatrics and infectious diseases. He chairs the UK Department of Health and Social Care’s Joint Committee on Vaccination and Immunisation and the European Medicines Agency scientific advisory group on vaccines and is a member of WHO’s SAGE. He was elected to the Academy of Medical Sciences in 2016 and is an NIHR Senior Investigator. His recent recognitions include the Bill Marshall award of the European Society for Paediatric Infectious Disease (ESPID) in 2013 for his contribution to the specialty, and the ESPID Distinguished Award for Education & Communication in 2015.

Professor Pollard received the medal in a ceremony on 27 September and delivered a lecture in the Children's Hospital at Uppsala.

About the award

The prize commemorates Nils Rosén von Rosenstein (1706-1773), a Swedish physician and the founder of modern paediatrics. Following studies at the universities of Lund and Uppsala, Rosén von Rosenstein travelled to several European countries and obtained a medical degree in Haarderwijk in 1730. He subsequently returned to take up a lectureship in Uppsala, where he was Carl Linnaeus’ contemporary. In 1743 he was appointed royal physician. In 1764, Rosén von Rosenstein published “The diseases of children, and their remedies”, considered to be the first modern textbook on the subject.

Similar stories

Professor Matthew Snape named NIHR Senior Investigator

Awards & Appointments Vaccinology

Four academics supported by the NIHR Oxford Biomedical Research Centre have been awarded a prestigious national award, among them Matthew Snape from the Oxford Vaccine Group.

Coronavirus vaccination linked to substantial reduction in hospitalisation, real-world data suggests

COVID-19 Research Vaccinology

The first study to describe the effects in real-world communities of the Oxford coronavirus vaccine has been reported in a pre-print publication today, showing a clear reduction in the risk of hospitalisation from COVID-19 amongst those who have received the vaccine.

Oxford vaccine effective against major B.1.1.7 ‘Kent’ coronavirus strain circulating in the UK

COVID-19 Research Vaccinology

A preprint of ongoing work to assess effectiveness of Oxford’s ChAdOx1 coronavirus vaccine shows that the existing vaccine has similar efficacy against the B.1.1.7 ‘Kent’ coronavirus strain currently circulating in the UK to previously circulating variants.

Oxford leads first trial investigating dosing with alternating vaccines

COVID-19 Clinical Trials Vaccinology

The University of Oxford is to lead the first trial to explore alternating different COVID-19 vaccines, to explore the potential for flexibility in delivery and look for clues as to how to increase the breadth of protection against new virus strains.

Oxford University vaccine developer joins day of vaccinations at the Kassam Stadium

COVID-19 Vaccinology

Today, Andrew Pollard, Professor of Pediatric Infection and Immunity at the University of Oxford, and chief investigator of the trials of the ChAdOx1 nCoV-19 coronavirus vaccine, volunteered his time to help deliver live-saving Covid vaccinations at the newly opened NHS Vaccine Centre at the Kassam Stadium, Oxford.

First peer-reviewed results of phase 3 human trials of Oxford coronavirus vaccine demonstrate efficacy

COVID-19 Vaccinology

University of Oxford and AstraZeneca researchers present a pooled analysis of Phase 3 trials of a vaccine against SARS-CoV-2 across two different dose regimens, resulting in an average efficacy of 70.4%.